BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36228146)

  • 1. Very early-onset behavioral variant frontotemporal dementia in a patient with a variant of uncertain significance of a
    Aguzzoli CS; Battista P; Hadad R; Ferreira Felloni Borges Y; Schilling LP; Miller BL
    Neurocase; 2022 Aug; 28(4):403-409. PubMed ID: 36228146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
    Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
    Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
    Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
    Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct early symptoms in neuropathologically proven frontotemporal lobar degeneration.
    Kawakami I; Arai T; Shinagawa S; Niizato K; Oshima K; Ikeda M
    Int J Geriatr Psychiatry; 2021 Jan; 36(1):38-45. PubMed ID: 32748432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
    Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
    Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS).
    Chornenka K; Hirsch-Reinshagen V; Perez-Rosendahl M; Feldman H; Segal-Gidan F; Vinters HV; Mackenzie IR
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):809-812. PubMed ID: 32483606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontotemporal lobar degeneration: diversity of FTLD lesions.
    Seilhean D; Bielle F; Plu I; Duyckaerts C
    Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
    Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
    J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.
    Hofmann JW; Seeley WW; Huang EJ
    Annu Rev Pathol; 2019 Jan; 14():469-495. PubMed ID: 30355151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapidly progressive Fronto-temporal dementia (FTD) associated with Frontotemporal lobar degeneration (FTLD) in the presence of Fused in Sarcoma (FUS) protein: a rare, sporadic, and aggressive form of FTD.
    Bradfield NI; McLean C; Drago J; Darby DG; Ames D
    Int Psychogeriatr; 2017 Oct; 29(10):1743-1746. PubMed ID: 28660843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.
    Mann DMA; Snowden JS
    Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FET) With Corticobasal Features and Language Deficits.
    Goodwill V; Coughlin D; Pizzo D; Galasko D; Hansen LA; Yuan SH; Hiniker A
    J Neuropathol Exp Neurol; 2021 Sep; 80(9):890-892. PubMed ID: 33969424
    [No Abstract]   [Full Text] [Related]  

  • 15. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.
    Seltman RE; Matthews BR
    CNS Drugs; 2012 Oct; 26(10):841-70. PubMed ID: 22950490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.
    Nicolas G; Sévigny M; Lecoquierre F; Marguet F; Deschênes A; Del Pelaez MC; Feuillette S; Audebrand A; Lecourtois M; Rousseau S; Richard AC; Cassinari K; Deramecourt V; Duyckaerts C; Boland A; Deleuze JF; Meyer V; Clarimon Echavarria J; Gelpi E; Akiyama H; Hasegawa M; Kawakami I; Wong TH; Van Rooij JGJ; Van Swieten JC; Campion D; Dutchak PA; Wallon D; Lavoie-Cardinal F; Laquerrière A; Rovelet-Lecrux A; Sephton CF
    Acta Neuropathol Commun; 2022 Feb; 10(1):20. PubMed ID: 35151370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement and characterization of distinctive clinical phenotypes using the Frontotemporal Lobar Degeneration Module (FTLD-MOD).
    Gefen T; Teylan MA; Besser L; Pollner E; Moshkovich A; Weintraub S
    Alzheimers Dement; 2020 Jun; 16(6):918-925. PubMed ID: 32400973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's in a name? Neuronal intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration-intermediate filament (FTLD-IF) or frontotemporal lobar degeneration-fused in sarcoma (FTLD-FUS)?
    Menon R; Baborie A; Jaros E; Mann DM; Ray PS; Larner AJ
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1412-4. PubMed ID: 21084263
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical characterization of bvFTD due to FUS neuropathology.
    Lee SE; Seeley WW; Poorzand P; Rademakers R; Karydas A; Stanley CM; Miller BL; Rankin KP
    Neurocase; 2012; 18(4):305-17. PubMed ID: 22060063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration.
    Rohrer JD; Lashley T; Schott JM; Warren JE; Mead S; Isaacs AM; Beck J; Hardy J; de Silva R; Warrington E; Troakes C; Al-Sarraj S; King A; Borroni B; Clarkson MJ; Ourselin S; Holton JL; Fox NC; Revesz T; Rossor MN; Warren JD
    Brain; 2011 Sep; 134(Pt 9):2565-81. PubMed ID: 21908872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.